FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1903461125> ?p ?o ?g. }

• W1903461125 abstract "Background Peripheral arterial disease (PAD) causes considerable morbidity and mortality. Hypertension is a risk factor for PAD. Treatment for hypertension must be compatible with the symptoms of PAD. Controversy regarding the effects of beta‐adrenoreceptor blockade for hypertension in patients with PAD has led many physicians to stop prescribing beta‐adrenoreceptor blockers. Little is known about the effects of other classes of anti‐hypertensive drugs in the presence of PAD. This is the second update of a Cochrane review first published in 2003. Objectives To determine the effects of anti‐hypertensive drugs in patients with both raised blood pressure and symptomatic PAD in terms of the rate of cardiovascular events and death, symptoms of claudication and critical leg ischaemia, and progression of atherosclerotic PAD as measured by ankle brachial index (ABI) changes and the need for revascularisation (reconstructive surgery or angioplasty) or amputation. Search methods For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (last searched March 2013) and CENTRAL (2013, Issue 2). Selection criteria Randomised controlled trials (RCTs) of at least one anti‐hypertensive treatment against placebo or two anti‐hypertensive medications against each other, with interventions lasting at least one month. Trials had to include patients with symptomatic PAD. Data collection and analysis Data were extracted by one author (DAL) and checked by the other (GYHL). Potentially eligible studies were excluded when the results presentation prevented adequate extraction of data and enquiries to authors did not yield raw data. Main results Eight RCTs were included with a total of 3610 PAD patients. Four studies compared a recognised class of anti‐hypertensive treatment with placebo and four studies compared two anti‐hypertensive treatments with each other. Studies were not pooled due to the variation of the comparisons and the outcomes presented. Overall the quality of the available evidence was unclear, primarily as a result of a lack of detail in the study reports on the randomisation and blinding procedures and incomplete outcome data. Two studies compared angiotensin converting enzyme (ACE) inhibitors against placebo. In one study there was a significant reduction in the number of cardiovascular events in patients receiving ramipril (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.91; n = 1725). In the second trial using perindopril (n = 52) there was a marginal increase in claudication distance but no change in ABI and a reduction in maximum walking distance. A trial comparing the calcium antagonist verapamil versus placebo in patients undergoing angioplasty (n = 96) suggested that verapamil reduced restenosis (per cent diameter stenosis (± SD) 48.0% ± 11.5 versus 69.6% ± 12.2; P < 0.01), although this was not reflected in the maintenance of a high ABI (0.76 ± 0.10 versus 0.72 ± 0.08 for verapamil versus placebo). Another study (n = 80) demonstrated no significant difference in arterial intima‐media thickness (IMT) in men receiving the thiazide diuretic hydrochlorothiazide (HCTZ) compared to those receiving the alpha‐adrenoreceptor blocker doxazosin (‐0.12 ± 0.14 mm and ‐0.08 ± 0.13 mm, respectively; P = 0.66). A study (n = 36) comparing telmisartan to placebo found a significant improvement in maximum walking distance at 12 months with telmisartan (median (interquartile range (IQR)) 191 m (157 to 226) versus 103 m (76 to 164); P < 0.001) but no differences in ABI (median (IQR) 0.60 (0.60 to 0.77) versus 0.52 (0.48 to 0.67)) or arterial IMT (median (IQR) 0.08 cm (0.07 to 0.09) versus 0.09 cm (0.08 to 0.10)). Two studies compared the beta‐adrenoreceptor blocker nebivolol with either the thiazide diuretic HCTZ or with metoprolol. Both studies found no significant differences in intermittent or absolute claudication distance, ABI, or all‐cause mortality between the anti‐hypertensives. A subgroup analysis of PAD patients (n = 2699) in a study which compared a calcium antagonist‐based strategy (verapamil slow release (SR) ± trandolapril) to a beta‐adrenoreceptor blocker‐based strategy (atenolol ± hydrochlorothiazide) found no significant differences in the composite endpoints of death, non‐fatal myocardial infarction or non‐fatal stroke with or without revascularisation (OR 0.90, 95% CI 0.76 to 1.07 and OR 0.96, 95% CI 0.82 to 1.13, respectively). Authors' conclusions Evidence on the use of various anti‐hypertensive drugs in people with PAD is poor so that it is unknown whether significant benefits or risks accrue. However, lack of data specifically examining outcomes in PAD patients should not detract from the overwhelming evidence on the benefit of treating hypertension and lowering blood pressure." @default.
• W1903461125 created "2016-06-24" @default.
• W1903461125 creator A5050407708 @default.
• W1903461125 creator A5068556161 @default.
• W1903461125 date "2013-12-04" @default.
• W1903461125 modified "2023-10-14" @default.
• W1903461125 title "Treatment of hypertension in peripheral arterial disease" @default.
• W1903461125 cites W113714250 @default.
• W1903461125 cites W1520966623 @default.
• W1903461125 cites W180946569 @default.
• W1903461125 cites W1964858352 @default.
• W1903461125 cites W1965618515 @default.
• W1903461125 cites W1965670200 @default.
• W1903461125 cites W1966044207 @default.
• W1903461125 cites W1973968263 @default.
• W1903461125 cites W1980889000 @default.
• W1903461125 cites W1983119172 @default.
• W1903461125 cites W1983526026 @default.
• W1903461125 cites W1987775247 @default.
• W1903461125 cites W1991628789 @default.
• W1903461125 cites W1994038899 @default.
• W1903461125 cites W1995542114 @default.
• W1903461125 cites W1998532291 @default.
• W1903461125 cites W1999992781 @default.
• W1903461125 cites W2003009625 @default.
• W1903461125 cites W2004122631 @default.
• W1903461125 cites W2004833857 @default.
• W1903461125 cites W2006694478 @default.
• W1903461125 cites W2019678113 @default.
• W1903461125 cites W2019749098 @default.
• W1903461125 cites W2022582118 @default.
• W1903461125 cites W2027041310 @default.
• W1903461125 cites W2027367469 @default.
• W1903461125 cites W2028871874 @default.
• W1903461125 cites W2029574194 @default.
• W1903461125 cites W2030914104 @default.
• W1903461125 cites W2033455696 @default.
• W1903461125 cites W2037605109 @default.
• W1903461125 cites W2044546685 @default.
• W1903461125 cites W2045833473 @default.
• W1903461125 cites W2046276038 @default.
• W1903461125 cites W2047111627 @default.
• W1903461125 cites W2056832458 @default.
• W1903461125 cites W2057386253 @default.
• W1903461125 cites W2061430540 @default.
• W1903461125 cites W2070691523 @default.
• W1903461125 cites W2071429496 @default.
• W1903461125 cites W2082336558 @default.
• W1903461125 cites W2083380872 @default.
• W1903461125 cites W2084457229 @default.
• W1903461125 cites W2093166691 @default.
• W1903461125 cites W2095230892 @default.
• W1903461125 cites W2102505453 @default.
• W1903461125 cites W2109547013 @default.
• W1903461125 cites W2110101054 @default.
• W1903461125 cites W2114236657 @default.
• W1903461125 cites W2118711079 @default.
• W1903461125 cites W2121682799 @default.
• W1903461125 cites W2122659928 @default.
• W1903461125 cites W2129991662 @default.
• W1903461125 cites W2133217116 @default.
• W1903461125 cites W2137246434 @default.
• W1903461125 cites W2137947658 @default.
• W1903461125 cites W2140136269 @default.
• W1903461125 cites W2141871159 @default.
• W1903461125 cites W2144148493 @default.
• W1903461125 cites W2144985796 @default.
• W1903461125 cites W2147910779 @default.
• W1903461125 cites W2148172060 @default.
• W1903461125 cites W2150174446 @default.
• W1903461125 cites W2152798629 @default.
• W1903461125 cites W2154988124 @default.
• W1903461125 cites W2160999195 @default.
• W1903461125 cites W2166512895 @default.
• W1903461125 cites W2167557672 @default.
• W1903461125 cites W2172032309 @default.
• W1903461125 cites W2255411386 @default.
• W1903461125 cites W2273475552 @default.
• W1903461125 cites W2312999996 @default.
• W1903461125 cites W2315630371 @default.
• W1903461125 cites W2324019134 @default.
• W1903461125 cites W2329086250 @default.
• W1903461125 cites W2393280676 @default.
• W1903461125 cites W2396772514 @default.
• W1903461125 cites W2416207717 @default.
• W1903461125 cites W2416542070 @default.
• W1903461125 cites W2417252370 @default.
• W1903461125 cites W4211163417 @default.
• W1903461125 cites W4248658461 @default.
• W1903461125 cites W4300056947 @default.
• W1903461125 doi "https://doi.org/10.1002/14651858.cd003075.pub3" @default.
• W1903461125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24307487" @default.
• W1903461125 hasPublicationYear "2013" @default.
• W1903461125 type Work @default.
• W1903461125 sameAs 1903461125 @default.
• W1903461125 citedByCount "40" @default.
• W1903461125 countsByYear W19034611252012 @default.
• W1903461125 countsByYear W19034611252013 @default.
• W1903461125 countsByYear W19034611252014 @default.
• W1903461125 countsByYear W19034611252015 @default.

• next